S 47445

Drug Profile

S 47445

Alternative Names: Ampakine-CX-1632; CX-1632; S47445

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer ADIR; RespireRx Pharmaceuticals; Servier
  • Class Antidementias; Small molecules
  • Mechanism of Action AMPA receptor modulators; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Major depressive disorder
  • Phase I Dementia; Mild cognitive impairment

Most Recent Events

  • 16 Jul 2017 Updated pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
  • 06 Apr 2017 Servier completes a phase II trial in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in Bulgaria, Slovakia, Hungary, Russia, Ukraine, Czech Republic and Finland (PO) (NCT02805439)
  • 29 Apr 2016 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in Bulgaria and Slovakia (PO) (EudraCT2015-003867-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top